Terug
19
30
Dagbereik
€ 28,30
€ 28,93
52-Weeksbereik
€ 24,24
€ 36,80
Volume
1.577.730
50D / 200D Gem.
€ 33,13
/
€ 30,45
Vorige Slotkoers
€ 28,16
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 21,7 | 0,4 |
| P/B | 3,4 | 2,9 |
| ROE % | 15,2 | 3,7 |
| Net Margin % | 3,7 | 3,9 |
| Rev Growth 5Y % | 13,2 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Hold
€ 38,14
+34.2%
Low: € 35,00
High: € 42,00
Forward K/W
15,2
Forward WPA
€ 1,87
WPA Groei (sch.)
+0,0%
Omzet Sch.
5,9 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 2,85
€ 2,80 – € 2,90
|
8,3 B | 1 |
| FY2029 |
€ 2,58
€ 2,54 – € 2,62
|
7,7 B | 1 |
| FY2028 |
€ 2,44
€ 2,44 – € 2,45
|
7 B | 3 |
Belangrijkste Punten
Revenue grew 13,22% annually over 5 years — strong growth
ROE of 15,20% — decent returns on equity
Debt/Equity of 0,00 — conservative balance sheet
Generating 258,45M in free cash flow
Cash machine — converts 124,50% of earnings into free cash flow
Capital efficient — spends only 0,00% of revenue on capex
Groei
Revenue Growth (5Y)
13,22%
Revenue (1Y)13,03%
Earnings (1Y)-2,00%
FCF Growth (3Y)-11,43%
Kwaliteit
Return on Equity
15,20%
ROIC19,11%
Net Margin3,67%
Op. Margin5,98%
Veiligheid
Debt / Equity
0,00
Current Ratio1,53
Interest Coverage2,70
Waardering
P/E Ratio
21,72
P/B Ratio3,40
EV/EBITDA12,66
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13,03% | Revenue Growth (3Y) | 14,59% |
| Earnings Growth (1Y) | -2,00% | Earnings Growth (3Y) | -11,84% |
| Revenue Growth (5Y) | 13,22% | Earnings Growth (5Y) | 10,37% |
| Profitability | |||
| Revenue (TTM) | 5,65B | Net Income (TTM) | 207,59M |
| ROE | 15,20% | ROA | 6,01% |
| Gross Margin | 19,26% | Operating Margin | 5,98% |
| Net Margin | 3,67% | Free Cash Flow (TTM) | 258,45M |
| ROIC | 19,11% | FCF Growth (3Y) | -11,43% |
| Safety | |||
| Debt / Equity | 0,00 | Current Ratio | 1,53 |
| Interest Coverage | 2,70 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 21,72 | P/B Ratio | 3,40 |
| P/S Ratio | 0,80 | PEG Ratio | 5,98 |
| EV/EBITDA | 12,66 | Dividend Yield | 0,00% |
| Market Cap | 4,51B | Enterprise Value | 4,28B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5,65B | 5,00B | 4,30B | 3,94B | 3,44B |
| Net Income | 207,59M | 211,82M | 267,09M | 150,56M | 139,90M |
| EPS (Diluted) | 1,28 | 1,23 | 1,48 | 0,83 | 0,77 |
| Gross Profit | 1,09B | 1,01B | 981,22M | 866,92M | 779,61M |
| Operating Income | 337,91M | 321,83M | 314,60M | 240,23M | 190,84M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3,46B | 3,42B | 3,33B | 3,23B | 2,93B |
| Total Liabilities | 2,13B | 2,02B | 1,91B | 1,85B | 1,75B |
| Shareholders' Equity | 1,33B | 1,40B | 1,42B | 1,39B | 1,18B |
| Total Debt | 0,0 | 1,22B | 1,17B | 1,16B | 1,16B |
| Cash & Equivalents | 232,62M | 412,57M | 343,85M | 294,19M | 119,42M |
| Current Assets | 1,26B | 1,32B | 1,09B | 994,34M | 710,26M |
| Current Liabilities | 829,35M | 780,15M | 618,31M | 565,35M | 459,70M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#970 of 1024
#368 of 616
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026